Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp; Monika E. Hegi; Warren Mason; Martin J. van den Bent; Martin Taphoorn; Robert C. Janzer; Samuel K. Ludwin; Anouk Allgeier · The Lancet Oncology · 2009
Zugriff auf die Ressource
Öffnen Sie den Inhalt über die Hauptoption oder wählen Sie eine andere verfügbare Quelle.
Ressourcenseite
Zitieren
Elegí el formato que necesitás y copiá la referencia al portapapeles.
APA 7
Stupp, R, Hegi, M. E, Mason, W, Bent, M. J. V. D, Taphoorn, M, Janzer, R. C, Ludwin, S. K, & Allgeier, A. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. https://doi.org/10.1016/s1470-2045(09)70025-7
MLA
Stupp, Roger, et al. "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial." 2009. https://doi.org/10.1016/s1470-2045(09)70025-7.
Chicago
Stupp, Roger, Monika E. Hegi, Warren Mason, Martin J. van den Bent, Martin Taphoorn, Robert C. Janzer, Samuel K. Ludwin, and Anouk Allgeier. 2009. "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.". https://doi.org/10.1016/s1470-2045(09)70025-7.
Harvard
Stupp, R. et al. 2009, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, available at: https://doi.org/10.1016/s1470-2045(09)70025-7 [Accessed 8 Aug. 2026].
Ressourcendetails
Bibliografische Angaben zur Prüfung, ob es sich um das richtige Material handelt.
- Titel
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- Autor / Mitwirkende
- Roger Stupp; Monika E. Hegi; Warren Mason; Martin J. van den Bent; Martin Taphoorn; Robert C. Janzer; Samuel K. Ludwin; Anouk Allgeier
- Verlag
- The Lancet Oncology
- Erscheinungsjahr
- 2009
- Sprache
- Inglés
Schlagwörter
Entdecken Sie über diese Schlagwörter weitere verwandte Ressourcen.